SPL.AX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 mai 2024 @ 08:10):

Stats
Dagens volum	766 718
Gjennomsnittsvolum	360 709
Markedsverdi	49.44M
EPS	$0 ( 2024-02-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.00
ATR14	$0 (0.00%)

Starpharma Holdings Ltd Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Starpharma Holdings Ltd Økonomi

Annual	2023
Omsetning:	$2.94M
Bruttogevinst:	$1.22M (41.60 %)
EPS:	$-0.0400

FY	2023
Omsetning:	$2.94M
Bruttogevinst:	$1.22M (41.60 %)
EPS:	$-0.0400

FY	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$0

FY	2022
Omsetning:	$4.68M
Bruttogevinst:	$1.91M (40.71 %)
EPS:	$-0.0400

Financial Reports:

No articles found.

Starpharma Holdings Ltd

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.